Impacto da obesidade sarcopênica na mortalidade e no início da terapia dialítica em pacientes com doença renal crônica

Abstract

The concomitant occurrence of obesity and sarcopenia has been attracting the attention of researchers around the world in different populations, and in chronic kidney disease it is no different. Associated with the great concern that, concurrently with senescence, there is an increase in visceral fat and a reduction in skeletal muscle mass, triggering a series of harmful health consequences associated with pathophysiological changes, there is no consensus in the literature on the diagnosis or treatment of sarcopenic obesity in patients with chronic kidney disease. In this sense, the present study sought to evaluate the impact of sarcopenic obesity on predialysis chronic kidney disease on the outcomes of death and renal replacement therapy. After analyzing the data obtained in the sample, it was possible to verify a high incidence of mortality among the studied population (39% of the sample). Analyzing the dichotomized sample in individuals with and without sarcopenic obesity, it was also possible to verify a difference in the lipid profile, in the VLDL (p= 0.043) and Glucose (p= 0.045) variables. Through the treatment and robust analysis of the data excluding possible confounders, a direct association between the progression of chronic kidney disease and low skeletal muscle strength of the evaluated patients became evident, p= 0.003 for death and p= 0.029 for referral to renal replacement therapy.